Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107861 · ClinicalTrials.gov registry record · Phase 1
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00107861 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 44 participants.
The verdict
NCT00107861, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: * to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; * help determine whether the virus carrying the interferon-beta gene will enter the bloodstream and liver tumor cells and cause the cancer cells to die.
Interventions
- DRUG Ad.hIFN-β (BG00001, IDEC-201)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107861
The ClinicalTrials.gov registry entry for NCT00107861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad.hIFN-β (BG00001, IDEC-201) is the first listed.
NCT00107861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107861 about?
NCT00107861 is a clinical study titled "Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases". This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: * to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; * help determine whether the virus carrying the interferon-beta...
What is the current status of trial NCT00107861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2005-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00107861?
The interventions under investigation include: Ad.hIFN-β (BG00001, IDEC-201) (DRUG).
Who is sponsoring clinical trial NCT00107861?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.